Trial Profile

A Phase 1b/2a clinical study of SACT-1 in neuroblastoma patients

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 23 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SACT 1 (Primary)
Indications Neuroblastoma
Focus Adverse reactions
Sponsors Aptorum Group

Most Recent Events

22 Jun 2023 According to Aptorum media release, the company announced that the group has submitted the relevant Phase 1b/2a clinical trial protocol of SACT-1, an orally administered repurposed small molecule drug for the treatment of neuroblastoma to US FDA.
03 Mar 2023 According to Aptorum media release, FDA has generally agreed on proposed clinical development plan for this study.
03 Mar 2023 According to Aptorum media release, company has announced the completion of an end of phase I (EOP1) meeting with the US Food and Drug Administration.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com